Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. (CMOPF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cmopf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cosmo Pharmaceuticals N.V. (CMOPF) measures how much investors pay for each dollar of the company's trailing earnings. CMOPF's current PE ratio of N/A is calculated by dividing its stock price of $90.00 by its TTM earnings per share of -$0.23.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 12 fiscal years · Front-end computedMinQ1 · 25%73.8x
MedianQ3 · 75%486.4x
Max
At N/A, CMOPF's current P/E is lower than in 0% of its annual fiscal year readings over the past 12 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cosmo Pharmaceuticals N.V.You CMOPF | $1.5B | N/A | — | -$0.23 |
 China Traditional Chinese Medicine Holdings Co. Limited CHIZF | $1.4B | N/A | — | -$0.07 |
 Evotec SE EVOTF | $1.2B | N/A | — | -$0.58 |
 Genetic Technologies Limited GNTLF | $1.3B | N/A | — | -$0.09 |
 Kissei Pharmaceutical Co., Ltd. KSPHF | $1.3B | 12.26x | -12.1% | $333.61 |
 SSY Group Limited LJUIF | $1.2B | 19.53x | +40.1% | $0.16 |
 Nippon Shinyaku Co., Ltd. NPPNY | $1.8B | 10.04x | -28.0% | $116.97 |
Industry Average 3 peers with valid PE | — | 13.94x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.23 | — | |
2024-12-31 FY2024 | 7.94x | $8.14 | — | |
2023-12-31 FY2023 | — | $-0.31 | — | |
2022-12-31 FY2022 | 61.36x | $1.05 | +23.9% | |
2021-12-31 FY2021 | 49.51x | $1.29 | — | |
2020-12-31 FY2020 | — | $-0.55 | — | |
2019-12-31 FY2019 | — | $-1.67 | — | |
2018-12-31 FY2018 | — | $-1.20 | — | |
2017-12-31 FY2017 | — | $-2.19 | — | |
2016-12-31 FY2016 | 111.27x | $1.37 | +1223.5% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cosmo Pharmaceuticals N.V. (CMOPF) measures how much investors pay for each dollar of the company's trailing earnings. CMOPF's current PE ratio of N/A is calculated by dividing its stock price of $90.00 by its TTM earnings per share of -$0.23.
Frequently asked questions
CMOPF pe ratio · 6 questionsCMOPF's current PE ratio is N/A as of 2026-06-08, based on a stock price of $90.00 and TTM EPS of -$0.23. Data sourced from Financial Modeling Prep via CMOPF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cosmo Pharmaceuticals N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08